1.An unusual cause of acute abdomen and acute renal failure: Djenkolism
Sumitro Kosasih ; Yong CS ; Tan Lian Tat ; Sandy Choo ; Lim Chiao Yuen ; Shariman H ; Anand J ; Chong VH
Malaysian Family Physician 2020;15(2):50-52
Te djenkol bean (Archidendron pauciforum) is a native delicacy in Southeast Asia, though
consumption can sometimes lead to djenkolism. Clinical features of djenkolism include acute
abdominal pain, hematuria, urinary retention, and acute kidney injury (AKI). Te pain can be
severe, which often leads to a misdiagnosis of acute abdomen. In this paper, we report the case of
an Indonesian migrant with djenkolism. Due to the short history and severity of the abdominal
pain, medical professionals suspected acute abdomen and proceeded with a negative exploratory
laparotomy. However, djenkolism was suspected once relatives informed the professionals that the
patient had consumed djenkol beans hours earlier. Te patient recovered through aggressive hydration
and urine alkalinization with bicarbonate infusion. We highlight the importance of being aware of
this rare cause of AKI, especially in Southeast Asia, in order to provide early diagnoses and prompt
treatments.
2.Antimicrobial profile of lactic acid bacteria isolated from vegetables and indigenous fermented foods of India against clinical pathogens using microdilution method.
Ami PATEL ; Nihir SHAH ; Padma AMBALAM ; J B PRAJAPATI ; Olle HOLST ; Asa LJUNGH
Biomedical and Environmental Sciences 2013;26(9):759-764
3.Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen
Zoe D. MICHAEL ; Srinath KOTAMARTI ; Rohith ARCOT ; Kostantinos MORRIS ; Anand SHAH ; John ANDERSON ; Andrew J. ARMSTRONG ; Rajan T. GUPTA ; Steven PATIERNO ; Nadine J. BARRETT ; Daniel J. GEORGE ; Glenn M. PREMINGER ; Judd W. MOUL ; Kevin C. OEFFINGER ; Kevin SHAH ; Thomas J. POLASCIK ;
The World Journal of Men's Health 2023;41(3):631-639
Purpose:
Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients. We examined initial longitudinal outcomes of mid-life men with an elevated baseline prostate-specific antigen (PSA) following initiation of a novel screening program within a system-wide network.
Materials and Methods:
We assessed our primary care network patients ages 40 to 49 years with a PSA measured following implementation of an electronic health record screening algorithm from 2/2/2017–2/21/2018. The multidisciplinary algorithm was developed taking factors including age, race, family history, and PSA into consideration to provide a personalized approach to urology referral to be used with shared decision-making. Outcomes of men with PSA ≥1.5 ng/mL were evaluated through 7/2021. Statistical analyses identified factors associated with PCa detection. Clinically significant PCa (csPCa) was defined as Gleason Grade Group (GGG) ≥2 or GGG1 with PSA ≥10 ng/mL.
Results:
The study cohort contained 564 patients, with 330 (58.5%) referred to urology for elevated PSA. Forty-nine (8.7%) underwent biopsy; of these, 20 (40.8%) returned with PCa. Eleven (2.0% of total cohort and 55% of PCa diagnoses) had csPCa. Early referral timing (odds ratio [OR], 4.58) and higher PSA (OR, 1.07) were significantly associated with PCa at biopsy on multivariable analysis (both p<0.05), while other risk factors were not. Referred patients had higher mean PSAs (2.97 vs. 1.98, p=0.001).
Conclusions
Preliminary outcomes following implementation of a multidisciplinary screening algorithm identified PCa in a small, important percentage of men in their forties. These results provide insight into baseline PSA measurement to provide early risk stratification and detection of csPCa in patients with otherwise extended life expectancy. Further follow-up is needed to possibly determine the prognostic significance of such mid-life screening and optimize primary care physician-urologist coordination.
4.The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han NG ; Kai En CHAN ; Yip Han CHIN ; Rebecca Wenling ZENG ; Pei Chen TSAI ; Wen Hui LIM ; Darren Jun Hao TAN ; Chin Meng KHOO ; Lay Hoon GOH ; Zheng Jye LING ; Anand KULKARNI ; Lung-Yi Loey MAK ; Daniel Q HUANG ; Mark CHAN ; Nicholas WS CHEW ; Mohammad Shadab SIDDIQUI ; Arun J. SANYAL ; Mark MUTHIAH
Clinical and Molecular Hepatology 2022;28(3):565-574
Background/Aims:
Nonalcoholic fatty liver disease (NAFLD) is closely associated with diabetes. The cumulative impact of both diseases synergistically increases risk of adverse events. However, present population analysis is predominantly conducted with reference to non-NAFLD individuals and has not yet examined the impact of prediabetes. Hence, we sought to conduct a retrospective analysis on the impact of diabetic status in NAFLD patients, referencing non-diabetic NAFLD individuals.
Methods:
Data from the National Health and Nutrition Examination Survey 1999–2018 was used. Hepatic steatosis was defined with United States Fatty Liver Index (US-FLI) and FLI at a cut-off of 30 and 60 respectively, in absence of substantial alcohol use. A multivariate generalized linear model was used for risk ratios of binary outcomes while survival analysis was conducted with Cox regression and Fine Gray model for competing risk.
Results:
Of 32,234 patients, 28.92% were identified to have NAFLD. 36.04%, 38.32% and 25.63% were non-diabetic, prediabetic and diabetic respectively. Diabetic NAFLD significantly increased risk of cardiovascular disease (CVD), stroke, chronic kidney disease, all-cause and CVD mortality compared to non-diabetic NAFLD. However, prediabetic NAFLD only significantly increased the risk of CVD and did not result in a higher risk of mortality.
Conclusions
Given the increased risk of adverse outcomes, this study highlights the importance of regular diabetes screening in NAFLD and adoption of prompt lifestyle modifications to reduce disease progression. Facing high cardiovascular burden, prediabetic and diabetic NAFLD individuals can benefit from early cardiovascular referrals to reduce risk of CVD events and mortality.